Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease

Abstract This paper reviews the relative abilities of magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission tomography (SPECT), and proton magnetic resonance spectroscopy (MRS) to detect Parkinson’s disease and monitor its progression. Currently, the main role of MRI lies in its ability to discriminate atypical syndromes from Parkinson’s disease; however, new volumetric approaches may soon allow progression of nigral degeneration to be followed. Proton MRS can also detect reduced levels of putamen N-acetyl aspartate (NAA) in many patients with atypical parkinsonian syndromes. PET and SPECT are both sensitive means of detecting the presence of impaired dopamine terminal function in the striatum and following its progression. PET currently has the greater spatial resolution and provides the added advantages that it also allows extra-striatal dopaminergic function to be monitored.

[1]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[2]  H. Kimura,et al.  Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.

[3]  M Otsuka,et al.  Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[4]  J S Rakshi,et al.  Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.

[5]  W. Poewe,et al.  The differential diagnosis of Parkinson's disease. , 2002, European journal of neurology.

[6]  G A Johnson,et al.  Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. , 1986, Radiology.

[7]  Clinical and [ 18 F ] dopa PET findings in early Parkinson ' s disease , .

[8]  H Lundqvist,et al.  Monoamine re‐uptake sites in the human brain evaluated in vivo by means of 11C‐nomifensine and positron emission tomography: the effects of age and Parkinson's disease , 1988, Acta neurologica Scandinavica.

[9]  K. Frey,et al.  Binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific , 1995 .

[10]  D J Brooks,et al.  An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. , 1996, Brain : a journal of neurology.

[11]  M Schulzer,et al.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism , 1994, Annals of neurology.

[12]  F. Fazio,et al.  Differential distribution of striatal [123I]β-CIT in Parkinson’s disease and progressive supranuclear palsy, evaluated with single-photon emission tomography , 1998, European Journal of Nuclear Medicine.

[13]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[14]  A. Bol,et al.  Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy , 1989, Annals of neurology.

[15]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[16]  T. Ishikawa,et al.  Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  F. Grandas,et al.  Progressive supranuclear palsy and corticobasal ganglionic degeneration: differentiation by clinical features and neuroimaging techniques. , 1994, Journal of neural transmission. Supplementum.

[18]  D. Margouleff,et al.  Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease , 1993, Annals of neurology.

[19]  D J Burn,et al.  Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study , 1997, Annals of neurology.

[20]  C. Marsden,et al.  Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.

[21]  G. Sawle,et al.  Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. , 1994, Archives of neurology.

[22]  Sid Gilman,et al.  Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography , 1988, Annals of neurology.

[23]  W. Oertel,et al.  123I‐IBZM binding compared with long‐term clinical follow up in patients with de novo parkinsonism , 1998, Movement disorders : official journal of the Movement Disorder Society.

[24]  A. Bol,et al.  Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration , 1989, Annals of neurology.

[25]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[26]  David J. Brooks,et al.  A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  G Di Chiro,et al.  Multiple system atrophy (Shy-Drager syndrome): MR imaging. , 1986, Radiology.

[28]  H. Fukuda,et al.  Striatal Dopamine D2 Receptors in Parkinson’s Disease and Striato-Nigral Degeneration Determined by Positron Emission Tomography , 1990 .

[29]  A J Lees,et al.  Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography. , 1988, Brain : a journal of neurology.

[30]  Eileen O. Smith,et al.  Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.

[31]  M. Bergstrom,et al.  Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism. , 1987, Advances in neurology.

[32]  S. Fahn,et al.  Study of movement disorders and brain iron by MR. , 1987, AJR. American journal of roentgenology.

[33]  E. Ciceri,et al.  Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. , 1994, Journal of neural transmission. Supplementum.

[34]  T Jones,et al.  The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. , 1990, Archives of neurology.

[35]  R A Zimmerman,et al.  Olivopontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy. , 1990, Radiology.

[36]  T Jones,et al.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[37]  M Hutchinson,et al.  Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra , 1999, Journal of neurology, neurosurgery, and psychiatry.

[38]  David H. Miller,et al.  Proton magnetic resonance spectroscopy in steele‐richardson‐olszewski syndrome , 1997, Movement disorders : official journal of the Movement Disorder Society.

[39]  S H Snyder,et al.  Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease , 1993, Annals of neurology.

[40]  Karl J. Friston,et al.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.

[41]  Y. Agid,et al.  Loss of Striatal [76Br]Bromospiperone Binding Sites Demonstrated by Positron Tomography in Progressive Supranuclear Palsy , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  A. Lang,et al.  Striatal dopamine distribution in Parkinsonian patients during life , 1985, Journal of the Neurological Sciences.

[43]  J. P. Seibyl,et al.  [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease , 1996, Neurology.

[44]  G. Sawle.  The rate of progression of Parkinson's disease , 1992, Annals of neurology.

[45]  J. Rinne,et al.  Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.

[46]  D J Brooks,et al.  Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[47]  Eileen O. Smith,et al.  123I beta-CIT Assessment of progression in Parkinsons disease , 1997 .

[48]  Paola Piccini,et al.  The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.

[49]  Y Tateno,et al.  Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[50]  Y. Kuwabara,et al.  Cerebral blood flow, oxygen and glucose metabolism with PET in progressive supranuclear palsy , 1989, Annals of nuclear medicine.

[51]  Richard S. J. Frackowiak,et al.  Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography , 1992, Annals of neurology.

[52]  J. Degroot,et al.  Magnetic resonance imaging of the midbrain in Parkinson's disease , 1986, Annals of neurology.

[53]  S J Kish,et al.  [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease , 1997, Neurology.

[54]  M Konagaya,et al.  Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[55]  D J Brooks,et al.  Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[56]  G. Antoni,et al.  Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography , 1990, Acta neurologica Scandinavica.

[57]  Dopamine D 1 receptors in Parkinson ' s disease and striatonigral degeneration : a positron emission tomography study , .

[58]  T. Gasser,et al.  123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism , 1992, Neurology.

[59]  C Nahmias,et al.  Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate , 1987, Journal of neurochemistry.

[60]  C D Marsden,et al.  The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. , 1990, Brain : a journal of neurology.